Role of CD44 in the invasiveness of glioblastoma multiforme and the noninvasiveness of meningioma: An immunohistochemistry study

Picker, 1989, Monoclonal antibodies to human lymphocyte homing receptors define a novel class of adhesion molecules on diverse cell types, J Cell Biol, 109, 927, 10.1083/jcb.109.2.927 Stamenkovic, 1991, The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells, EMBO J, 10, 343, 10.1002/j.1460-2075.1991.tb07955.x Kuppner, 1992, Differential expression of the CD44 molecule in human brain tumours, Int J Cancer, 50, 572, 10.1002/ijc.2910500414 Rutka, 1988, The extracellular matrix of the central and peripheral nervous systems: Structure and function, J Neurosurg, 69, 155, 10.3171/jns.1988.69.2.0155 Carter, 1988, A characterization of the class III collagen receptor: A phosphorylated, transmembrane glycoprotein expressed in nucleated human cells, J Biol Chem, 263, 4193, 10.1016/S0021-9258(18)68908-2 Lesley, 1990, Binding of hyaluronic acid to lymphoid cell lines is inhibited by monoclonal antibodies against Pgp1, Exp Cell Res, 187, 224, 10.1016/0014-4827(90)90085-O Aruffo, 1990, CD44 is the principal cell surface receptor for hyaluronate, Cell, 61, 1303, 10.1016/0092-8674(90)90694-A Miyake, 1990, Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition, J Exp Med, 172, 69, 10.1084/jem.172.1.69 Gunthert, 1991, A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells, Cell, 65, 13, 10.1016/0092-8674(91)90403-L Li, 1993, Variant CD44 adhesion molecules are expressed in human brain metastases but not in glioblastomas, Cancer Res, 53, 5345 Jalkanen, 1986, Homing receptors and the control of lymphocyte migration, Immunol Rev, 91, 39, 10.1111/j.1600-065X.1986.tb01483.x Omary, 1988, Structural heterogeneity of human Pgp-1 and its relationship with p85, Immunogenetics, 27, 460, 10.1007/BF00364434 Gallatin, 1989, Structural homology between lymphocyte-homing receptors and extracellular matrix receptor type. III, 86, 4654 Fox, 1993, CD44 and cancer screening, Lancet, 342, 548, 10.1016/0140-6736(93)91670-H Tölg, 1993, Splicing choice from ten variant exons establishes CD44 variability, Nucleic Acids Res, 21, 1225, 10.1093/nar/21.5.1225 Jalkanen, 1986, A distinct endothelial cell recognition system that control lymphocyte traffic into inflamed synovium, Science, 233, 556, 10.1126/science.3726548 Matsumura, 1992, Significance of CD44 gene products for cancer diagnosis and disease evaluation, Lancet, 340, 1053, 10.1016/0140-6736(92)93077-Z Jackson, 1993, CD44 and cancer, Lancet, 341, 252, 10.1016/0140-6736(93)90126-2 Tarin, 1993, CD44 and cancer, Lancet, 341, 252, 10.1016/0140-6736(93)90126-2 Pilkington, 1994, Tumour cell migration in the nervous system, Brain Pathol, 4, 157, 10.1111/j.1750-3639.1994.tb00826.x Penno, 1994, Expression of CD44 in human lung tumors, Cancer Res, 54, 1381 Asher, 1992, Hyaluronate binding and CD44 expression in human glioblastoma cells and astrocytes, Exp Cell Res, 203, 80, 10.1016/0014-4827(92)90042-7 Girgrah, 1991, Localization of the CD44 glycoprotein to fibrous astrocytes in normal white matter and to reactive astrocytes in active lesions in multiple sclerosis, J Neuropathol Exp Neurol, 50, 779, 10.1097/00005072-199111000-00009 Seiter, 1993, Prevention of tumor metastasis formation by anti-variant CD44, J Exp Med, 177, 443, 10.1084/jem.177.2.443